AD Hypotheses and Suggested Clinical Trials

ACS Chem Neurosci. 2021 Nov 3;12(21):3968-3971. doi: 10.1021/acschemneuro.1c00627. Epub 2021 Oct 18.

Abstract

Alzheimer's disease (AD) is a major neurodegenerative disorder that impairs cognitive reserve impacting activities of daily living. The prime pathological characteristics of AD include the deposition of neurofibrillary tangles of hyperphosphorylated tau (τ) proteins, accumulation of amyloid-β (Aβ), and neuronal loss. Expanding literature suggests that oxidative stress (OS) is a vital factor contributing to the pathogenesis of AD such that biometals (e.g., iron, zinc, copper) are believed to play a crucial role in Aβ formation and neurodegeneration. Growing evidence indicates the impact of OS in AD, and clinical trials with antioxidative therapeutic interventions are in the frontline of AD research. We discuss various AD hypotheses and associated clinical trials. We present a case for future therapeutic intervention for AD by putting forth postulated hypotheses and trials.

Keywords: Alzheimer’s disease; Aβ peptide; antioxidants; cognitive reserve; glutathione; neurodegenerative diseases; neurofibrillary tangles; oxidative stress.

Publication types

  • Case Reports

MeSH terms

  • Activities of Daily Living
  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides
  • Humans
  • Neurofibrillary Tangles
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • tau Proteins